Publications by authors named "Dileep Dasyam"
Inno4Vac, a public-private partnership funded by the IMI2/EU/EFPIA Joint Undertaking (IMI2 JU), brings together academic institutions, SMEs, and pharmaceutical companies to accelerate and de-risk vaccine development. The project has made significant strides in the selection and production of challenge agents for influenza, respiratory syncytial virus (RSV), and toxigenic Clostridioides difficile for controlled human infection model studies (CHIMs). A regulatory workshop held on March 20, 2024, addressed the standardisation of clinical procedures, ethical considerations, endpoints, and data integrity, highlighting the ongoing initiatives related to these CHIMs.
View Article and Find Full Text PDFArticle Synopsis
- Clostridioides difficile (C. difficile) is a major cause of healthcare-related diarrhea, with issues like antibiotic resistance and high relapse rates complicating treatment.
- *Faecal microbiota transplantation is a potential therapy but understanding the key factors for successful colonization resistance is necessary for its broader application.
- *Experts highlighted the need for a Controlled Human Infection Model (CHIM) to safely study mild to moderate C. difficile infections, which could lead to new treatments and better insights into how the infection works.*